Board of Directors

Jeremy Green

Chair

Investor Director representing Redmile

Lisa Anson

Chief Executive Officer

Experienced General Manager, former President of AstraZeneca UK

Appointed in 2018, Lisa Anson has led the transformation of Redx into a clinical stage biotech with two programmes in clinical development and a growing pipeline of preclinical assets. During this time the company also secured major partnership deals for five assets with large and speciality pharma and secured long term financing with new blue chip life science focused investors.

Prior to joining Redx, Lisa had significant leadership experience in global pharmaceuticals over a 20-year career at AstraZeneca plc with her appointment in 2012 as President of AstraZeneca UK having held a series of senior commercial leadership roles in the company both the US and the UK. Lisa is also a key player in the industry, and in 2018 she was elected to the Board of the Bio Industry Association (BIA).  Previously Lisa has been President of the Association of the British Pharmaceutical Industry (ABPI) and member of the board, where she chaired several UK industry committees and worked closely with the UK Government. Lisa started her career as a management consultant in London before moving to California with a cancer disease management company.

Lisa holds an MBA (awarded with distinction) from INSEAD, France and a First-Class honours degree in Natural Sciences from Cambridge University in the UK. Lisa currently lives in Cheshire with her husband and three children.

Peter Presland

Non-Executive Director

Finance, Audit and Corporate Governance specialist with several high profile organisations

Peter Presland joined the Board in November 2017 and has nearly 50 years’ experience in business, much of that at the highest levels of management within both public and private companies. A law graduate at King’s College, London, he also qualified as a Chartered Accountant with Arthur Andersen. In 1980, he joined C E Heath Plc, a major publicly quoted international insurance Group, as Group Accountant/Treasurer and became in 1985 the youngest ever PLC Director when appointed Group Finance Director at the age of 34. He was promoted to become Heath’s Group Chief Executive in 1990, and in 1996, he devised the demerger of C E Heath’s computer services operations into a separate publicly listed company, Rebus Group Plc, becoming its Chief Executive and in 1999 its Executive Chairman. Shareholders doubled their money in three years.

Since 2001, Peter has pursued a portfolio Non-Executive career. These appointments include the Chairmanship in 2003 of LINK, the UK ATM network, where he led a major corporate governance change and completed the merger of LINK with Voca, the provider of the BACS service, becoming Chairman of VocaLink in 2007. From 2012 to 2015, he served as Chairman of the Audit and Governance Committee of East Kent Hospitals NHS Trust and in 2019 was asked to become Chairman of the Governance and Finance Committee of The Lord’s Taverners, a high-profile charity. Peter is currently Chairman of Ashington Innovation PLC, a recently listed special purpose acquisition company.

Dr Bernhard Kirschbaum

Non-Executive Director

Former Executive Vice-President of Global Research at Merck Serono

Bernhard Kirschbaum joined the Board in January 2016. Bernd has over 25 years’ experience in pharmaceutical research and drug development, having held leadership roles at Merck/Merck Serono, Sanofi-Aventis, Aventis and Hoechst Marion Roussel. He has expertise in a broad range of disease areas including oncology, immuno-oncology, immunology, neurological disorders and cardiometabolic diseases. In the eight years to 2013, he worked at Merck/Merck Serono, becoming a member of the Board and Executive Vice-President, Global Research & Early Development. He was responsible for a budget of 1 billion euros and a global team of over 2,500 associates. In his last three years at Merck Serono, he led the successful growth of the company’s R&D portfolio, with over 70 programmes, doubling the number of Phase II assets in this period.

Bernd is currently Chairman of OMEICOS Therapeutics and GQ Bio-Therapeutics and a board member of BioMedX and Amarna Therapeutics as well as an advisor to the board of KAHR Medical.

Dr Claire Catherinet

Non-Executive Director

Investor Director representing Sofinnova

Claire Catherinet joined the Board in May 2024 and is a Senior Associate at Sofinnova Partners – Crossover Strategy, a leading life-sciences venture capital firm.

Claire joined Sofinnova in 2021, having previously been an analyst on the Life Sciences team at Andera Partners where she identified and invested in biotech and medtech companies. Claire has a PhD in Hemato-Oncology from Paris Diderot University, an MSc from Agrocampus Ouest and a degree in Biopharmaceutical Management from ESCP Business School. Her research has been published in journals such as Nature Communications and Cancer Cell.

Natalie Berner

Non-Executive Director

Investor Director representing Redmile

Natalie joined Redx as a Non-Executive Director in May 2021 and brings extensive experience in the healthcare sector to the Board. She is a Managing Director focusing on Therapeutics at Redmile, which she joined in 2016. Prior to Redmile, Natalie was a Research Associate at the New York University School of Medicine. Natalie received a BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University.